Menu
Search
|

Menu

Close
X

Incyte Corp INCY.OQ (NASDAQ Stock Exchange Global Select Market)

85.34 USD
-1.74 (-2.00%)
As of Mar 22
chart
Previous Close 87.08
Open 86.75
Volume 464,222
3m Avg Volume 597,216
Today’s High 87.01
Today’s Low 85.30
52 Week High 88.76
52 Week Low 57.01
Shares Outstanding (mil) 214.05
Market Capitalization (mil) 18,266.88
Forward P/E 169.30
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.05 Mean rating from 20 analysts

KEY STATS

Revenue (mm, USD)
FY18
1,882
FY17
1,536
FY16
1,106
EPS (USD)
FY18
0.504
FY17
-1.558
FY16
0.538
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
169.30
58.10
Price to Sales (TTM)
vs sector
9.71
8.84
Price to Book (MRQ)
vs sector
9.45
4.60
Price to Cash Flow (TTM)
vs sector
111.07
40.07
Total Debt to Equity (MRQ)
vs sector
0.91
17.66
LT Debt to Equity (MRQ)
vs sector
0.91
13.97
Return on Investment (TTM)
vs sector
5.28
12.12
Return on Equity (TTM)
vs sector
6.16
13.24

EXECUTIVE LEADERSHIP

Herve Hoppenot
Chairman of the Board, President, Chief Executive Officer, Since 2015
Salary: $966,505.00
Bonus: --
Christiana Stamoulis
Chief Financial Officer, Executive Vice President, Since 2019
Salary: --
Bonus: --
Paula Swain
Executive Vice President - Human Resources, Since 2002
Salary: $343,346.00
Bonus: --
Barry Flannelly
Executive Vice President and General Manager - US, Since 2015
Salary: --
Bonus: --
Vijay Iyengar
Executive Vice President, Global Strategy and Corporate Development, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1801 Augustine Cut off
WILMINGTON   DE   19803-4404

Phone: +1302.4986700

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

SPONSORED STORIES